<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03085238</url>
  </required_header>
  <id_info>
    <org_study_id>MTRAP-2016-01</org_study_id>
    <nct_id>NCT03085238</nct_id>
  </id_info>
  <brief_title>Metastatic Tumor Cell Trap Device in Patients With Advanced Ovarian Cancer</brief_title>
  <official_title>Safety and Performance of Metastatic Tumor Cell Trap Device in Patients With Advanced Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MTrap, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedPass International</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>MTrap, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      M-Trap is an implantable medical device designed to capture disseminated tumor cells (DTCs).
      It is intended for use in advanced-stage ovarian cancer patients. The study objective is to
      assess the safety and the performance of the M-Trap device.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 9, 2017</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, multi-center, non-blinded, single-arm study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Freedom from device and procedure related major adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Freedom from device and procedure related major adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance: Histological evidence of tumor cell capture</measure>
    <time_frame>6 months</time_frame>
    <description>Histological evidence of tumor cell capture</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Long-term adverse event reporting</measure>
    <time_frame>18 months</time_frame>
    <description>Long-term adverse event reporting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance: Disease focalization score</measure>
    <time_frame>18 months</time_frame>
    <description>Disease focalization score</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Ovarian Cancer Stage IIIC</condition>
  <arm_group>
    <arm_group_label>M-Trap</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>M-Trap</intervention_name>
    <description>Device(s) will be surgically implanted in the peritoneal cavity.</description>
    <arm_group_label>M-Trap</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is a female ≥18 years old.

          2. Presents with a diagnosis of Stage IIIC ovarian cancer.

          3. Presents with high-grade serous carcinoma.

          4. Has one of the following:

               1. Visible residual tumor ≤1 cm after primary tumor debulking surgery.

               2. Three cycles of neoadjuvant chemotherapy and complete resection after interval
                  tumor debulking surgery.

               3. Three cycles of neoadjuvant chemotherapy and visible residual tumor ≤1 cm after
                  interval tumor debulking surgery.

          5. ECOG performance status of 0 or 1.

          6. Is willing to comply with required follow-up study visits.

          7. Is willing and able to provide written informed consent.

        Exclusion Criteria:

          1. Has a life expectancy of &lt;3 months.

          2. Is pregnant, as confirmed through a blood test prior to any study procedure, planning
             on becoming pregnant during the study, or is lactating.

          3. Will be receiving intraperitoneal chemotherapy.

          4. Has undergone prior treatment with abdominal and/or pelvic radiotherapy.

          5. Has significant active concurrent medical illnesses including, but not limited to,
             ongoing or active infection, symptomatic congestive heart failure, unstable angina
             pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
             limit compliance with study requirements.

          6. Presence of central nervous system or cerebral metastases.

          7. Recurrent ovarian cancer.

          8. Complete resection with no residual tumor after primary tumor debulking surgery.

          9. Suboptimal resection with &gt;1 cm residual tumor after primary or interval tumor
             debulking surgery.

         10. Is simultaneously enrolled in another investigational study.

         11. Has a history of cancer within 5 years other than in-situ uterine cervix cancer or
             non-melanoma skin cancer.

         12. Has a known hypersensitivity to carboplatin or paclitaxel.

         13. Is concurrently using other antineoplastic agents.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Gil-Moreno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vall d'Hebron</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Castellon University General Hospital</name>
      <address>
        <city>Castelló</city>
        <zip>12004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz Madrid</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valencia-Hospital General</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitrio y Politècnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2017</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

